EFFICACY AND SAFETY OF MONOTHERAPY AND COMBINATION THERAPY OF ORAL MINOXIDIL FOR ANDROGENETIC ALOPECIA: A STRUCTURED REVIEW

By

Safrin Jahan 18346058

A thesis submitted to the School of Pharmacy in partial fulfillment of the requirements for the degree of Bachelor of pharmacy

School of Pharmacy Brac University November 2022

© 2022. Brac University All rights reserved.

Declaration

It is hereby declared that

- 1. The thesis submitted is my own original work while completing degree at Brac University.
- 2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
- 3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
- 4. I have acknowledged all main sources of help.

Student's Full Name & Signature:

Safrin Jahan

18346058

Approval

The thesis titled "Efficacy and safety of monotherapy and combination therapy of oral minoxidil for androgenetic alopecia: A structured review" submitted by Safrin Jahan (18346058) of Summer 2018 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor of Pharmacy on 30th January 2023.

Supervised By

Dr. Mesbah Talukder Professor, School of Pharmacy BRAC University

Approved By

Assistant Dean & Program Director:

Dr. Hasina Yasmin Assistant Dean & Program Director, School of Pharmacy BRAC University

Dean:

Dr. Eva Rahman Kabir Dean, School of Pharmacy BRAC University

Ethics Statement

This project is a review article and it does not involve any animal trials or clinical trials on humans.

Abstract

In both men and women, AGA is a condition where dihydrotestosterone resulting from testosterone attacks hair follicles. OM is an FDA approved antihypertensive vasodilator. OM is an antihypertensive vasodilator authorized by FDA but not authorized for hair loss therapy. Despite this, low-dose oral minoxidil (LDOM) 0.25 to 5 milligram has displayed a favorable safety and effectiveness profile in numerous research studies (Jimenez-Cauhe, Saceda-Corralo et al. 2019, Vano-Galvan,, Pirmez et al., 2021). Oral minoxidil generates hypertrichosis and cardiovascular system (CVS) symptoms according to numerous clinical studies and the FAERS database. On the other hand, several clinical studies show that oral minoxidil in combination with spironolactone or dutasteride intralesional injections has less side effects than monotherapy of OM. As combination therapy data obtained are based on prospective, uncontrolled and open-label observational studies with and short follow-up. Thus, further studies are warranted for the safety and efficacy of combination therapies.

Keywords: Androgenetic alopecia; male pattern hair loss; Oral minoxidil; Spironolactone; Dutasteride intralesional microinjection

Acknowledgement

Bismillahir Rahmanir Rahim,

Firstly, I would like to express my deep sense of gratitude and indebtedness to my supervisor **Dr**. **Mesbah Talukder (Professor)** for his continuous patience and support. This project would not have been possible without the support of my advisor who read my numerous revisions and helped to make some sense of the confusion through offering me with proper guidance. His encouragement to write this thesis made me confident that the topic was worthy of my investigation and that my investigation was worthy of the topic. I have benefited greatly from his wealth of knowledge and meticulous editing. I am extremely grateful that he took me on as a student and continued to have faith in me.

I also extend gratitude and appreciation to my graduate committee members **Dr. Eva Rahman Kabir (Professor and Dean)** and **Dr. Hasina Yasmin (Professor, Assistant Dean and Program Director)** for their patience and understanding my efforts. Their encouraging words and thoughtful, detailed feedback have been very important to me.

I also wish to acknowledge the great support and advice of all my lecturers of School of Pharmacy, Brac University, who have taught me at one point or the other. May Allah SWT continue to bless and protect them.

Last but not least, I would want to express my profound gratitude to my family and friends, without whom the project could not have been completed in such a short amount of time.

Table of Contents

Declaration	n ii
Approval	iii
Ethics Stat	ementiv
Abstract/ I	Executive Summaryv
Acknowled	lgementvi
Table of C	ontentsvii
List of Tab	lesix
List of Fig	uresx
List of Acr	onymsxi
Glossary	xii
Chapter 1	Introduction1
Chapter 2	Sources and search strategy4
Chapter 3	Pharmacokinetics
4.1.	Absorption
4.2.	Distribution
4.3.	Metabolism
4.4.	Excretion7

Chapter 4	Pharmacodynamics10
Chapter 5	Efficacy12
5.1.	OM monotherapy12
5.2.	OM combination therapy12
5.2.2	1. OM 0.25 mg and spironolactone 25 mg14
5.2.2	2. Dutasteride intralesional microinjection and oral minoxidil 5 mg15
Chapter 6	Safety17
6.1.	ОМ17
6.1.1	. Pregnant and lactating mothers
6.1.2	1. Impact of OM intake within males on female companions
6.2.	Topical minoxidil19
Chapter 7	Conclusion21
References	

List of Tables

Table 1: PICO Table	.3
Table 2: Pharmacokinetics of minoxidil oral dosage form	.8
Table 3: Efficacy of oral minoxidil in clinical studies	.13
Table 4: Efficacy of oral minoxidil combination therapy in clinical studies	.16
Table 5: Side effects of oral minoxidil vs topical (Clinical trial data)	.20
Table 6: Side effects of oral minoxidil vs topical (FAERS database)	20

List of Figures

Figure 1:	Search approach with inclusion and exclusion standards for the articles	5
Figure 2:	OM mechanisms to stimulate hair growth	11

List of Acronyms

- OM Oral Minoxidil
- SUR Sulfonylurea receptor
- DIM Dutasteride intralesional microinjections
- FPHL Female pattern hair loss
- AGA Androgenetic alopecia
- MPHL Male-pattern hair loss
- ATP Adenosine triphosphate
- VEGF Vascular endothelial growth factor

Glossary

Oral Minoxidil:	Oral Minoxidil is a vasodilator.
Sulfonylurea receptor:	Atypical ABC protein that regulates activity of the ATP channel.
Female pattern hair loss:	Pattern of hair loss caused by hormones, aging and genetics.
Male-pattern hair loss:	Pattern of receding hairline and hair thinning on the crown.
Dihydrotestosterone:	A hormone made from testosterone.
5a-reductase:	Converts testosterone to dihydrotestosterone.

Introduction

Androgenetic alopecia, hair loss disorder that influences both male and female. It is an illness in which testosterone-derived dihydrotestosterone (DHT) attacks hair follicles, causing hair to fall out and cease growing. It tends to affect the top and front of the scalp hair. It can trigger a variety of mental health problems, notably reduction of self-confidence, increased self-consciousness, poor self-respect, despair, and anxiousness. Only two therapies are currently authorized through the USFDA for the medication of androgenetic alopecia. All of those are finasteride and topical minoxidil. OM is an antihypertensive vasodilator authorized by the FDA. However, off-label usage of low-dose OM for the medication of MPHL is getting more priority than other medications used in the treatment of AGA. The FDA has not yet authorized it for hair loss therapy. Despite this, low-dose oral minoxidil (LDOM) 0.25 to 5 mg has displayed a favorable safety and effectiveness profile in numerous research studies. (Jimenez-Cauhe, Saceda-Corralo et al. 2019, Vano-Galvan, Pirmez et al., 2021). The overall plasma half-life is roughly 4 hours, and it boosts hair growth via a variety of mechanisms. Spironolactone is also frequently used in conjunction with other medications to treat hypertension and heart failure. Instead, when taken in conjunction with oral minoxidil for androgenetic alopecia, it prevents adverse effects. There were no incidents of hyperkalemia or other blood test anomalies. Similarly, oral route dutasteride (OD) is an effective and FDA-approved medicine for benign prostatic hyperplasia (BPH) as well as off-label for androgenetic alopecia (AGA). Only Japan and South Korea have authorized the 0.5 mg per day dosage for male AGA. Along with a plasma half-life of around 5 weeks and suppresses 5areductase (5AR), I as well as II class isoenzyme, reduction of DHT. Given the risk of negative

sexual anomalies from Dutasteride monotherapy, many male are unwilling to cure it with reductase inhibitors (DIM). As an outcome, when paired with oral minoxidil therapy, DIM may serve as a powerful antiandrogen substitute therapy for AGA. There is no oedema, infection, or just about any intralesional adverse effect with this multimodal treatment. All of these combinations might be a consideration, notably for individuals who have poor compliance with oral minoxidil therapy and want to boost their terminal hair count, hair diameter, and overall hair count. Oral minoxidil generates hypertrichosis and cardiovascular system (CVS) symptoms, according to numerous clinical studies and the FAERS database, whereas dutasteride monotherapy causes sexual dysfunction and neuropsychiatric negative impacts. Several clinical investigations, on the other hand, imply that coupling oral minoxidil with spironolactone or dutasteride intralesional injections had less side effects than OM monotherapy. Data from the SALT, Norwood Hamilton, and Sinclair scales are utilized to evaluate the effectiveness of adjunctive therapy. The SALT score is generated by dividing the percentage of hair loss from each of the four quadrants of the scalp by the surface area of the quadrant, then merging the four results to generate a summary measure. A SALT score of 100 implies full scalp hair loss, whereas a score of 0 denotes no hair loss. The Norwood Hamilton taxonomy, on the other hand, divides scalp into two primary categories: "not bald" and "bald." The "not bald" group incorporates varieties I-III, whereas the "bald" division covers varieties IV-VIII (Wirya, Wu et al. 2017). Furthermore, the Sinclair scale comprises five categories. The findings obtained for combination treatment are based on a prospective, uncontrolled, open-label observational trial with a short follow-up period(Kaneko and Kaneko 2018). As a result, further research on the safety and efficacy of concomitant medicines is required. This article examines the pharmacokinetics, effectiveness, pharmacodynamics and safety of OM monotherapy and concomitant therapy for the medication of AGA.

Table 1. PICO Table

Parameter	Inclusion	Exclusion
Patients	Patients of any age treated for androgenetic alopecia	Any other type of alopecia
Intervention	Oral minoxidil as alone or combination therapy	Other drugs as individual therapy except oral minoxidil
Comparator	The effectiveness of OM mono and combination therapy for treating hair loss	
Outcomes	End point measurements of hair parameters, terminal hair count, hair diameter and total hair count	

Sources and search strategy

On July 10 2022, They conducted an investigation in a structured way on pubmed, openathens and google scholar using keywords and medical subject heading terms for the safety and efficacy of OM mono and co- treatment of MPHL and FPHL varieties of AGA mechanism of action, pharmacokinetics and pharmacodynamics the search turns up 212 results the number was dropped to 142 after deduplication as well as the first screening the clinical studies exploring the safety and effectiveness of om mono and co-treatment for AGA were included in the paper. As a matter of fact, studies on all other sorts of alopecia such as alopecia universalis and alopecia areata were excluded Figure 1 depicts the inclusion and exclusion norms.




Figure 1. Search approach with inclusion and exclusion standards for the articles

Pharmacokinetics

3.1. Absorption

Most of the projected 90 percent of total OM is taken by the GIT. (Gupta et al., 2022). Furthermore, in a research 29 healthy non-obese individuals were given a 2.5 mg pill of OM where the ideal plasma max concentration as well as AUC of OM were calculated to be 16.8 ± 7.83 mg/mL and 25.3 ± 7.02 mg h/mL, respectively (Table 2) (Lowenthal and Affrime 1980, Fleishaker, Andreadis et al. 1989). Cmax was attained around 1 hour (Tmax) after medication delivery. Food has no consequence on the bioavailability of minoxidil, which may be taken before or after a meal.

3.2. Distribution

OM seems to have a VD upwards of 200 liters. Incapable of interacting to blood proteins and incapable of passing the BBB (blood-brain barrier) (Lowenthal and Affrime 1980).

3.3. Metabolism

A pro-drug called OM is activated inside the liver through the steps of glucuronidation, sulfation and hydroxylation (Table 2) (Fleishaker, Andreadis et al. 1989, Gupta, Talukder et al. 2022). Furthermore, OM is processed by follicular sulfotransferase generating minoxidil sulfate metabolites (active form) (Gupta et al., 2022). Patients who have more sulfotransferase expression are far more inclined to respond rapidly versus those who have lower sulfotransferase activity.

Minoxidil O-glucuronide represents the most abundant OM metabolite in humans ("LONITEN® | Pfizer", 2022).

3.4. Excretion

During a research 29 young normal volunteers were given OM 2.5 mg per day, the renal clearance of OM was estimated to be approximately 351.67 86.5 mL/min (Fleishaker, Andreadis et al. 1989). OM and its metabolites are almost always eliminated in the urine and, to a slightly lesser degree in the feces ("LONITEN® | Pfizer", 2022). It has a plasma half-life of nearly 4 hours on average and can last for consecutive days up to 72 hours ("LONITEN® | Pfizer", 2022).

Table 2. Pharmacokinetics of OM.

Para	meters	ОМ	
	Bioavailability	90 percentage of total	
	Cmax	16.8 ± 7.83 ng/mL	
	Tmax	30 min to 1hour	
Absorption	Area under curve	25.3 ± 7.02 ng hour per mL	
	Food ramification on Bioavailability	Unaffected by food	
	Drugs interacting to decrease efficacy	Acetylsalicylic acid	
	Vss or VD	<200 L	
Distribution	Plasma protein binding	Does not bind	
	BBB	Does not cross	
	Presence in semen	NR	

Metabolism		 Liver Major metabolite is glucuronide conjugate By glucuronidation, hydroxylation, and sulfation process 			
	Total clearance	351.67 ± 86.5 mL/min			
Excretion	Half-life	4.2 hours			
	Via	Majorly in urine and minorly in feces			

Pharmacodynamic

The effects of OM on cell and channel function are diverse. It boosts the formation of epithelial and fibroblast cellular processes, while also encouraging the extension of keratinocyte lifespan (Messenger and Rundegren 2004). PGE2 synthesis is also boosted, however prostacyclin formation is repressed (Messenger and Rundegren 2004). Sarcolemma potassium channel openers potentially aid hair development. Following OM sulphation, minoxidil sulphate operates on the SUR to liberate ATP from cells. The liberated ATP is therefore metabolized into adenosine by ATPase, which then interacts on adenosine receptors in DP cells to cause them to generate VEGF (Gupta, Talukder et al. 2022). Both lysyl hydroxylase and collagen manufacture are suppressed (Messenger and Rundegren 2004). Dermal papilla (DP) cells boost VEGF generation via adenosine (Gupta, Talukder et al. 2022).




Figure 2. OM mechanisms to stimulate hair growth.

Efficacy

5.1. OM monotherapy

Several clinical investigations used oral minoxidil at various dosages extending from 0.25 to 5 mg/d (Table 3) (Gupta, Talukder et al. 2022). As an outcome, daily intake of LDOM (0.25-5 mg daily) is less effective than minoxidil at 5 mg daily.

Type	Type of Dose	OM 2.5 – 5 mg per day	OM 1 mg per day	0	OM<2.5 mg once daily	
S	Study	Jha Sonthalia et al., 2020	Ramos et al., (2020)	Vahabi- Amlashi et al., (2021)	Vastarella et al., (2020)	Jha, Sonthalia et al., 2020
Stud	Study type	Open-label	Randomized	Randomized	Retrospective	Open-label
Di	Disease	Male AGA	FPHL	FPHL	FPHL	AGA
Dosage	Dosage regimen	5 mg daily (24 weeks)	1 mg daily (24 weeks)	0.25 mg daily(6 months)	1.5 to 2 mg daily	1.25 mg daily(6 months)
	Ν	30	26	6	12	32
	Total hair density (hairs/c m ²)	Before Treatment Baseline , 182.5 \pm 43.3, 208.5 \pm 42 (12 week).217.6 \pm 44.9 (24 week)	Before Treatment Baseline 164.6 ± 48.1, 184.7 (24-week)	Before Treatment Baseline 102.0 ± 50.76,112.2 ± 68.4 (6 month)	Before Treatment Baseline (on vertex arena): $136. \pm 51.30$, (vertex): 168.92 ± 58.59 (24 week), Baseline (frontal): 131.47 ± 36.11 , (frontal): 181.40 (24 week)	Before Treatment Baseline 48.4%
Result	Terminal hair density (hairs/c m ²)	Before Treatment Baseline, 153 ± 33, 178 ± 38 (12 week), 188.1 ± 37 (24 week),	Before Treatment Baseline 106.5 ± 34.2 112.62 (4 week)	Not Reported	Before Treatment Baseline (vertex): $68.66 \pm$ 32.56,97.75 \pm 45.08 (24 week), Before Treatment Baseline (frontal): 72.68 \pm 22.12, (frontal): 108.53 (24 week)	Not Reported
	Hair diameter (µm)	Before Treatment Baseline ,58.5 ± 11.8,64.7 ± 15.2 (12 week), 67.4 ± 4.5 (24 week)	Not Reported	Before Treatment Baseline 0.043 ± 0.001,0.045 (6-month)	Before Treatment Baseline (vertex): 0.04 ± 0.01 , (vertex): 0.05 ± 0.01 (24-week), Before Treatment Baseline (frontal): 0.04 ± 0.01 , (frontal): $0.05(At 24 week)$	Before Treatment Baseline 46, 50 $\pm 11.7 (12$ week) 68.1 \pm 11.6 (6 month)
Con	Comment	 For unmanageable hypertension. 	Low-dose oral minoxidil provides efficacy in FPHL	 OM 0.25 mg/day Shows insignificant difference 	 Overall 38 % and 23% improvement in hair density 	 Efficacies were not statistically different.

5.2. OM combination therapy

5.2.1. OM 0.25 mg and spironolactone 25 mg

One study claims that 100 women who have been detected with a range of 2 to 5 FPHL (Sinclair stage) were medicated for a year with a regular dosage of 25 mg of spironolactone in conjunction with OM 0.25 mg (Sinclair 2018). When the average age was 48.44 years, the baseline hair losing score was 4.82. At the start, the extremity of hair fall was 2.79. Minor adverse events in 8 women included face hypertrichosis (4), postural hypotension (2), and urticaria (2) (Sinclair 2018). On a clinical examination, nobody suffered from hyperkalemia or faced other anomalies. Six of the eight individuals who had adverse effects resumed their medication, whereas two patients with urticaria stopped it. At rest, the average systolic and diastolic blood pressures were 122.92 mmHg and 79.17 mmHg, correspondingly. Employing follow-up assessments, systolic and diastolic blood pressure was estimated toward being 118.40 and 72.69 following three months, with an average turnaround blood pressure of 4.52 mmHg (systolic) and blood pressure of 6.48 mmHg(diastolic)(Sinclair 2018). 22 participants projected a brief shoot up in hair fall 3 to 6 weeks after the very first stage of the therapy. Despite this, the majority of women saw very little hair falling out at three months and far more hair density at six months(Sinclair 2018). Likewise, in a 6-patient open-label, prospective, single-arm research employing OM with spironolactone more than a span of 5 to 13 months, 5 participants exhibited a 1-grade improvement, whereas 1 patient retained the same grade with a modest clinical improvement even without side effects (Olamiju and Craiglow 2021).

5.2.2. Dutasteride intralesional microinjection and oral minoxidil 5 mg

According to one survey, 58 subjects (55.5%) who underwent OM monotherapy as well as 47 (44.5%) whom received OM in association with DIM out of 105 male patients with an average age of 34.5 years were analyzed (Villarreal-Villarreal, Boland-Rodriguez et al. 2022). As per self - regulation, there was a substantial improvement in both groups: 34 (72.3%) in the OM+ DIM group vs. 37 (63.8%) in the OM monotherapy group (P = 0.589). Clinical assessment demonstrated statistically insignificant distinction amongst OM monotherapy and OM + DIM in the frontal area (P = 0.587), meanwhile a statistically considerable difference was found between the OM plus DIM and OM monotherapy groupings in the vertex area (P 0.001) (Villarreal-Villarreal, Boland-Rodriguez et al., 2022).

Table 4. Effectiveness of OM combination therapy in clinical studies

	Dose	Oral Minoxidil and	Dutasteride intralesional	Oral minoxidil 0.25
		spironolactone	microinjections (duta 1 ml +	mg and
		combination in	saline 1 ml) and oral	spironolactone 25 mg
		adolescent girls	minoxidil 5 mg	Once daily
	Study	(Olamiju & Craiglow, 2021)	(Villarreal-Villarreal et al., 2022)	(Sinclair,2017)
S	Study type	single-arm study	Retrospective analysis	Observational pilot study
[Disease	AGA	AGA	FPHL
Do	Dosage regimen	OM 2.5 mg in adjunct with spironolactone 50 mg/day for 13 months	Oral minoxidil 5 mg and DIM 1 mL/day respectively for 3 months	OM 0.25 mg in adjunct with spironolactone 25 mg/day respectively for 6 and 12
	N	9	47	100
		Baseline:	Baseline:	Baseline: Sinclair scale
		After 13 months	At 16-week:	Onset Hair shedding score
	Total hois donoite	Sinclair scale stage	Hamilton-Norwood	4.82
	10tal Itali Uclishy	Onset - 2	II - 2 (4.3%)	At 6-month: Reduced by
Result		After therapy -1	III - 24 (51.1%)	0.85
			IV - 14 (29.8%)	At 12-month:
			V - 5 (10.6%)	Reduced by 1.3
			VI - 2 (4.3%)	
	Terminal hair	Not Reported	Not Reported	Not Reported
	Hair diameter (µm)	Not Reported	Not Reported	Not Reported
		Eimitation of study	• Could be an alternative,	
		includes small	especially in men who are	• Could be an alternative,
	Comments	sample size and	reluctant to use reductase	who show minor
		retrospective nature.	inhibitors outcome unfavorable	compliance with OM or
			sexual anomalies.	topical minoxidil.

Safety

6.1. OM

LDOM somewhere around 0.25 to 5 mg per day generates CVS anomalies, hypertrichosis, as well as scalp pruritus or skin rashes, according to numerous clinical study data (Table 5) (Gupta et al., 2022). The dosage of OM determines when hypertrichosis and CVS symptoms emerge. Based on a six-month research, the probability of acquiring hypertrichosis and CVS symptoms jumps by 17.6% and 4.8% (Gupta et al., 2022), respectively, whenever the dose of 1 mg of OM is increased. According to the FAERS database (2000–2021), CVS symptoms are disclosed by the individuals who took Loniten for AGA (Table 6) ("FDA Adverse Event Reporting System (FAERS) Public Dashboard", 2022). Furthermore, volunteers employing OM 5 mg per day continued for about 24 weeks claiming that they had no extreme cardiovascular anomaly symptoms in a prospective study which included 34 male AGA patients (21-58 years) (Sanabria, Palmegiani et al. 2022). Additionally, in an investigation was aimed including 34 males (aged between 19 to 58) who received OM 5 mg per day continuing about 24 weeks, said not to have encountered extreme cardiovascular anomaly symptoms. Consequently, OM medication for 24 weeks is safe for male participants who have never experienced first-hand cardiovascular anomalies low dose OM 0.25 to 5mg once daily (Sanabria, Palmegiani et al. 2022). Four patients throughout all withdrew out of the research for various reasons, comprising two suffering headaches, one exhibiting edema, and single person suffering from a condition independent to the OM treatment (Sanabria, Palmegiani et al. 2022). After 24 weeks of therapy, the corresponding participant numbers have been

investigated again: 19 (55.9%) suffered hypertrichosis; 7 (20.6%) having headaches; one participant experienced edema and another participant experienced vertigo. The standard heart rate turnaround on week 24 was analytically minor (1.1%;95% CI;1.0 to 3.2%: p: 14.323), whereas a patient additionally exhibited tachycardia. Hence, 24 weeks of 5 mg/d OM therapy indicated in a minor decline in standard of (3%:, 95% CI;, 0.6 to 5.4%;, p: 14.015) arterial pressure (Sanabria, Palmegiani et al. 2022).

6.1.1. Pregnant and lactating mothers

OM is not advised for use by pregnant women or nursing mothers since it falls under pregnancy category C (hazard cannot be excluded out) (Gupta, Talukder et al. 2022). There are no reliable prenatal trials for category C medications. Neonatal hypertrichosis can be caused by OM. Additionally, OM may be passed in human milk during lactation and can be hazardous for newborns ("LONITEN® | Pfizer", 2022).

6.1.2. Impact of OM intake within males on female companions

Until now there is no documented OM secretion in semen and made the assumption that the amount excreted in semen is insignificant ("Minoxidil (Rogaine) | Parsa Mohebi", 2022). Before finalizing any recommendation, more investigation is essential, and the most recent statistics should be obtained from healthcare professionals. So far, it has not been established that using OM when their female companion is expecting is safe for men.

6.2. Topical minoxidil

According to one research, a total of 9 people may have experienced hypertrichosis. Additionally, headache was experienced by 25% of minoxidil 10% patients compared to just 11.1% of minoxidil 5% patients (Ghonemy, Alarawi et al. 2021). Especially in comparison to the 5% topical minoxidil group, only (55%) patients complained in the 10% minoxidil treatment group for all patients. There was no evidence of sexual side effects, vital sign alteration, or palpitation (Ghonemy, Alarawi et al. 2021). On table 6 it is stated that patients who used minoxidil 5% for AGA reported experiencing CVS symptoms ("FDA Adverse Event Reporting System (FAERS) Public Dashboard", 2022).

Side effects	Oral minoxidil			Topical minoxidil				
	< 2.5	5mg/d	2.5-5	5 mg/d	5	%	10)%
	Male	Female	Male	Female	Male	Female	Male	Female
CVS	2/57	6/63	12/30	Not	Not	Not	Not	Not
anomalies	(3.51%)	(9.52%)	(40.0%)	reported	reported	reported	reported	reported
Muscle	Not	Not	Not	Not	Not	Not	Not	Not
atrophy	reported	reported	reported	reported	reported	reported	reported	reported
Hypertrichosis	19/57	12/63	Not	Not	6/27	Not	Not	9/24
	(55.9%)	(19.04%)	reported	reported	(22.2%)	reported	reported	(37.5%)
CNS	Not	Not	Not	Not	Not	Not	Not	Not
anomalies	reported	reported	reported	reported	reported	reported	reported	reported
Scalp pruritus	Not	0/12	2/30	Not	1/19	Not	Not	Not
and skin	reported	(0.00%)	(6.63%)	reported	(3.2%)	reported	reported	reported
rashes								
Sexual	Not	Not	Not	Not	Not	Not	Not	Not
dysfunction	reported	reported	reported	reported	reported	reported	reported	reported

Table 5. Side effects of OM vs topical (Clinical trial statistic)

Table 6. Side effects of oral minoxidil vs topical (FAERS Database)

Side effects	Oral m	inoxidil	Topical mi	inoxidil 5%	
	Male	Female	Male	Female	
CVS symptoms	10/14 (71.43%)	Not reported	Not reported	Not reported	
Skin-related	Not reported	Not reported	Not reported	Not reported	
adverse events					
Hypertrichosis	Not reported	Not reported	Not reported	Not reported	
CNS symptoms	1/14 (7.14%)	Not reported	Not reported	Not reported	
Musculoskeletal	Not reported	Not reported	Not reported	Not reported	
side effects					
Sexual	Not reported	Not reported	1/1 (100%)	Not reported	
dysfunction					

Conclusion

Some clinics are still utilizing LDOM, which ranges from 0.25 to 5 mg/d, to treat AGA patients despite the fact that it is not authorized. Overall, mono and combination OM therapy might be potential evolution to the AGA treatment, particularly for people who shows adverse reactions experienced by the application or use of topical minoxidil and all the trending and ongoing AGA therapies or to avoid or how to manage the adverse effects. Thus, the safety and effectiveness of OM monotherapy and combination therapy still require further clinical studies and post-marketing data to be fully understood.

Reference

- Blume-Peytavi, U., et al. (2019). "Efficacy and safety of a new 5% minoxidil formulation in male androgenetic alopecia: A randomized, placebo-controlled, double-blind, noninferiority study." <u>J Cosmet Dermatol</u> 18(1): 215-220.
- Fleishaker, J. C., et al. (1989). "The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers." <u>J Clin Pharmacol</u> 29(2): 162-167.
- Ghonemy, S., et al. (2021). "Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation." J Dermatolog Treat 32(2): 236-241.
- Gupta, A. K., et al. (2022). "Minoxidil: a comprehensive review." J Dermatolog Treat 33(4): 1896-1906.
- Gupta, A. K., et al. (2022). "Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia." <u>J Dermatolog Treat</u>: 1-17.
- Jha, A. K., et al. (2020). "Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia." <u>J Am Acad Dermatol</u> 83(5): 1491-1493.
- Jimenez-Cauhe, J., et al. (2019). "Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia." <u>J Am Acad Dermatol</u> 81(2): 648-649.
- Kaneko, A. and T. Kaneko (2018). "A New Classification of Early Female Pattern Hair Loss." <u>Int J Trichology</u> 10(2): 61-67.

- Lowenthal, D. T. and M. B. Affrime (1980). "Pharmacology and pharmacokinetics of minoxidil." <u>J Cardiovasc Pharmacol</u> 2 Suppl 2: S93-106.
- Messenger, A. G. and J. Rundegren (2004). "Minoxidil: mechanisms of action on hair growth." <u>Br J Dermatol</u> 150(2): 186-194.
- Olamiju, B. and B. G. Craiglow (2021). "Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls." J Am Acad Dermatol 84(6): 1689-1691.
- Panchaprateep, R. and S. Lueangarun (2020). "Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment." <u>Dermatol Ther (Heidelb)</u> 10(6): 1345-1357.
- Pirmez, R. and C. I. Salas-Callo (2020). "Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation." <u>J Am Acad</u> <u>Dermatol</u> 82(1): e21-e22.
- 14. Ramos, P. M., et al. (2020). "Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial." <u>J Am Acad Dermatol</u> 82(1): 252-253.
- 15. Sanabria, B. D., et al. (2022). "Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia." <u>J Am Acad Dermatol</u>.
- 16. Sinclair, R. D. (2018). "Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone." <u>Int J Dermatol</u> **57**(1): 104-109.

- 17. Vahabi-Amlashi, S., et al. (2021). "A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss." <u>Dermatol Ther</u>
 34(6): e15131.
- Vano-Galvan, S., et al. (2021). "Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients." <u>J Am Acad Dermatol</u> 84(6): 1644-1651.
- Villarreal-Villarreal, C. D., et al. (2022). "Dutasteride intralesional microinjections in combination with oral minoxidil vs. oral minoxidil monotherapy in men with androgenetic alopecia: a retrospective analysis of 105 patients." J Eur Acad Dermatol Venereol 36(7): e570-e572.
- 20. Wirya, C. T., et al. (2017). "Classification of Male-pattern Hair Loss." <u>Int J Trichology</u> 9(3): 95-100.